Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Menthol cigarette use in US pregnancies: Prevalence, racial/ethnic disparities, and associated characteristics from the 2010-2019 National Survey on Drug Use and Health (NSDUH).
Nicotine Tob Res
January 2025
Behavioral Health and Health Policy, Westat, 1600 Research Blvd, Rockville, MD 20850, United States.
Introduction: Pregnant people who smoke constitute a uniquely vulnerable population likely to be impacted by a menthol cigarette (MC) ban. However, there are no published reports of prevalence of prenatal MC use in a nationally-representative US sample including racial-ethnic disparities and associated characteristics.
Methods: Participants were 1245 US pregnant people who smoked MC or non-MC (NMC) in the past 30-days from the 2010-2019 National Survey on Drug Use and Health.
An Algorithmic Overview of Advanced Pain Therapies: A Narrative Review.
Curr Pain Headache Rep
January 2025
Department of Pain Medicine, Division of Anesthesiology, Critical Care & Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Purpose Of Review: Quickly referenceable, streamlined, algorithmic approaches for advanced pain management are lacking for patients, trainees, non-pain specialists, and interventional specialists. This manuscript aims to address this gap by proposing a comprehensive, evidence-based algorithm for managing neuropathic, nociceptive, and cancer-associated pain. Such an algorithm is crucial for pain medicine education, offering a structured approach for patient care refractory to conservative management.
View Article and Find Full Text PDFGene-ius at work: Hemophilia B treatment enters a new era.
Am J Health Syst Pharm
January 2025
Department of Pharmacy Practice, Auburn University Harrison College of Pharmacy, Auburn, AL, USA.
Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.
View Article and Find Full Text PDFLazertinib: breaking the mold of third-generation EGFR inhibitors.
RSC Med Chem
January 2025
Department of Chemistry, The State University of New York at Buffalo Natural Sciences Complex Buffalo NY 14260 USA
Small molecules targeting activating mutations within the epidermal growth factor receptor (EGFR) are efficacious anticancer agents, particularly in non-small cell lung cancer (NSCLC). Among these, lazertinib, a third-generation tyrosine kinase inhibitor (TKI), has recently gained FDA approval for use in combination with amivantamab, a dual EGFR/MET-targeting monoclonal antibody. This review delves into the discovery and development of lazertinib underscoring the improvements in medicinal chemistry properties, especially in comparison with osimertinib.
View Article and Find Full Text PDFAdvancements in drug discovery: integrating CADD tools and drug repurposing for PD-1/PD-L1 axis inhibition.
RSC Adv
January 2025
LAQV and REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa Caparica Portugal
Despite significant strides in improving cancer survival rates, the global cancer burden remains substantial, with an anticipated rise in new cases. Immune checkpoints, key regulators of immune responses, play a crucial role in cancer evasion mechanisms. The discovery of immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 has revolutionized cancer treatment, with monoclonal antibodies (mAbs) becoming widely prescribed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!